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Abstract
Melanoma is an unpredictable, highly metastatic malignancy, and treatment of advanced 
melanoma remains challenging. Novel molecular markers based on the alterations in gene 
expression and the molecular pathways activated or deactivated during melanoma progression are 
needed for predicting the course of the disease already in primary tumors and for providing new 
targets for therapy. Here, we sought to identify genes whose expression in primary melanomas 
correlate with patient disease-specific survival using global gene expression profiling. Many of the 
identified potential markers of poor prognosis were associated with the epithelial-mesenchymal 
transition, extracellular matrix formation, and angiogenesis. We studied further the significance of 
one of the genes, prolyl 4-hydroxylase subunit alpha 1 (P4HA1), in melanoma progression. 
P4HA1 depletion in melanoma cells reduced cell adhesion, invasion, and viability in vitro. In 
melanoma xenograft assays, we found that P4HA1 knockdown reduced melanoma tumor invasion 
as well as the deposition of collagens, particularly type IV collagen, in the interstitial extracellular 
matrix and in the basement membranes of tumor blood vessels, leading to vessel wall rupture and 
hemorrhages. Further, P4HA1 knockdown reduced the secretion of collagen triple helix repeat 
containing 1 (CTHRC1), an important mediator of melanoma cell migration and invasion, in vitro 
and its deposition around tumor blood vessels in vivo. Taken together, P4HA1 is an interesting 
potential prognostic marker and therapeutic target in primary melanomas, influencing many 
aspects of melanoma tumor progression.
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1 Introduction
Cutaneous melanoma is one of the most aggressive malignancies and its incidence is still rising all 
over the world. Breslow’s tumor thickness, mitotic rate, and ulceration are considered to be the 
best prognostic factors predicting survival for patients diagnosed with localized disease (Balch et 
al., 2009). However, over 7% of patients with thin melanomas (Breslow’s thickness 0.51-1.0 mm) 
and a mitotic rate less than 1.00 mitoses/mm2 die within 10 years of diagnosis (Thompson et al., 
2011). These cases show that the survival outcome cannot be predicted on histopathological 
features alone. Further, the standard staging method for regional metastatic melanoma, the 
lymphatic mapping with invasive sentinel lymph node biopsy (and in case of a positive sentinel 
lymph node biopsy, completion lymphadenectomy), is associated with substantial morbidity. 
Additionally, about 10% of sentinel lymph node-negative patients with intermediate thickness 
(1.2-3.5 mm) primary melanomas and about 30% of sentinel lymph node-negative patients with 
thick (>3.5 mm) primary melanomas die of their disease within 5 years of diagnosis (Morton et 
al., 2014), suggesting the presence of false-negative results or spreading of the disease through 
other routes, such as the blood circulation. Also, despite the recent advances in targeted and 
immunotherapies, the treatment of advanced melanoma remains challenging. Therapies targeting 
the mutated BRAF are associated with high response rates, but only a subset of patients show 
prolonged disease control. Newer immunotherapies, in turn, induce more durable disease control 
in majority of the responders but have lower response rates (Silva and Long, 2017). The clinical 
and biological heterogeneity of melanomas call for novel, better molecular markers based on the 
molecular pathways activated or deactivated in melanoma progression for predicting the course of 
the disease and providing new targets for therapy.
Here, we sought to identify new molecules associated with melanoma progression and 
aggressiveness that could predict patient survival already in primary melanomas. We found that 
many of the identified potential prognostic marker genes were associated with the epithelial-
mesenchymal transition, extracellular matrix organization, collagen formation, and angiogenesis. 
Among others, high mRNA expression of the hypoxia-regulated P4HA1 gene, encoding the 
catalytic subunit of prolyl 4-hydroxylase, correlated highly significantly with shorter patient 
survival in an independent primary melanoma dataset. We further studied the function of P4HA1 
in melanoma by knocking it down and analyzing the effect on melanoma cell adhesion, invasion, 
and viability in vitro and tumorigenesis in vivo. We also show that prolyl 4-hydroxylase function A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd.
is essential for the secretion of collagen triple helix repeat containing 1 (CTHRC1), an important 
mediator of melanoma cell migration and invasion.
2 Materials and Methods
2.1 Patient samples
Primary cutaneous melanomas (n = 44) and benign nevi (n = 19) from healthy volunteers were 
obtained by surgical excision at Helsinki University Central Hospital using protocols approved by 
the Ethics Committee of Helsinki University Central Hospital. The study conformed to the 
standards set by the Declaration of Helsinki, and all patients provided informed consent. Half of 
each tissue specimen was fixed in formalin for histopathological and immunohistochemical 
analyses, and the other half was immediately frozen in liquid nitrogen or immersed in RNAlater 
RNA stabilization solution (Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA) for gene 
expression analyses using DNA microarrays and RT-PCR.
2.2 RNA isolation and purification
RNA was extracted from cells and tissues using the RNeasy kit (>200 nt RNA, Qiagen, Hilden, 
Germany). Frozen tissue specimens were ground in liquid nitrogen and homogenized in lysis 
buffer with a 21-gauge needle. Tissues immersed in RNAlater were homogenized in lysis buffer 
with Lysing matrix D and the FastPrep FP120 Cell Disrupter (Qbiogene/MP Biomedicals, Santa 
Ana, CA, USA) according to the manufacturer’s instructions. Pigment removal was performed by 
adsorption to Bio-Gel P-60 as described elsewhere (Soikkeli et al., 2007). The quality of the 
purified RNA was assessed by agarose gel electrophoresis or by Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA).
2.3 Microarray analysis and data analysis
Primary melanomas (n = 19) and benign nevi (n = 11) were analyzed using the Human Genome 
U133 Plus 2.0 array and normal melanocytes and melanoma cell lines (WM793 and WM239) 
using the Human Genome U133 set arrays (Affymetrix/Thermo Fisher Scientific), as previously 
described (Soikkeli et al., 2007).
The microarray probe signals were preprocessed using the RMA algorithm (Bolstad et al., 2003) 
in the Chipster v3.11.6 software (http://chipster.csc.fi/). Gene probe sets with a mean difference A
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<100 and a fold change <1.5 between the melanoma sample groups (alive or died of melanoma) 
were filtered off before searching for genes correlating with patient survival using Significance 
Analysis of Microarrays (SAM) 5.0 package (Tusher et al., 2001) (http://www-
stat.stanford.edu/~tibs/SAM/). SAM survival analysis was performed in R (version 3.4.0) 
(http://www.r-project.org/) using 4000 random permutations. Delta was chosen so that the false 
discovery rate was <1%.
Gene lists were subjected to Gene Set Enrichment Analysis (GSEA) using the Molecular 
Signature Database (MSigDB, v6.0, Broad institute, MA, USA, 
http://www.broadinstitute.org/gsea/msigdb/index.jsp) Hallmark gene sets. False discovery rate q-
values < 0.05 were considered significant. Correlating gene expression was analyzed with Pearson 
correlation using 0.35 as a cut-off value.
2.4 RT-PCR analyses
One µg of RNA was reverse transcribed into cDNA and used for semiquantitative PCR analysis as 
previously described (Soikkeli et al., 2007). Primers and PCR variables are listed in Table S1.
2.5 Histology and immunohistochemistry
Formalin-fixed paraffin-embedded sections (5 µm) were deparaffinized, rehydrated in a graded 
ethanol series, and subjected to routine hematoxylin and eosin (H&E) staining and Masson’s 
trichrome staining to discriminate collagen fibers from muscular tissues. For P4HA1 staining, 
sections were subjected to heat-induced epitope retrieval (HIER) in citrate buffer (0.01M, pH 6.0). 
HIER in Tris-EDTA buffer, pH 9.0 and trypsin treatment were also tested as the antigen retrieval 
methods in the evaluation phase of P4HA1 staining, the former giving equivalent results with the 
citrate buffer. The endogenous peroxidase activity was blocked with peroxidase-blocking solution 
(Dako/Agilent Technologies). A panel of P4HA1 antibodies (12658-1-AP, 1:100 and 66101-1-Ig, 
1:500 from Proteintech Group, Rosemont, IL, USA; NBP1-84398, 1:1000 from Novus 
Biologicals, Littleton, CO, USA; HPA007599, 1:200 from Atlas Antibodies, Bromma, Sweden) 
were tested for their performance in immunohistochemistry using primary melanoma samples 
showing high P4HA1 mRNA expression (Fig. S1), and the mouse monoclonal antibody 66101-1-
Ig was selected for the study. Sections were incubated with the primary antibody (1:500) in 
antibody diluent (Immunologic, Duiven, Netherlands) for 1 hour and detected using BrightVision A
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Poly-HRP kit (Immunologic) and 3-amino-9-ethylcarbatzole (AEC) as the chromogen. For 
cleaved caspase 3 staining, sections were subjected to HIER in citrate buffer (0.01M, pH 6.0), 
blocked with CAS-block containing 1.5% goat serum for 1 hour, incubated with the rabbit 
monoclonal antibody (#9664, Cell Signaling Technology, Leiden, Netherlands; 1:200) in PBS 
containing 0.1% goat serum at +4°C overnight, and detected with the Vectastain ABC kit (Vector 
Laboratories, Burlingame California) according to the manufacturer’s protocol using AEC as the 
chromogen. For CD31 staining, sections were subjected to HIER in Tris-EDTA buffer (pH 9.0) 
and incubated in a Tris-buffer (pH 7.5) containing 0.05% Triton X-100 for 10 minutes. 
Endogenous peroxidase activity was blocked with 0.3% H2O2 in PBS for 10 minutes. Sections 
were blocked in 2.5% goat serum in PBS for 1 hour, incubated with a rabbit polyclonal CD31 
antibody (ab124432, Abcam, 1:500) in PBS containing 0.1% goat serum at +4°C overnight, and 
detected with the Vectastain ABC kit using AEC. For type IV collagen (COL-IV) staining, 
sections were subjected to HIER in citrate buffer (CC2, Ventana/Roche, Basel, Switzerland) and 
protease treatment with protease 1 (Ventana/Roche). Sections were incubated with a mouse 
monoclonal COL-IV antibody (clone CIV22, ready-to-use, Ventana/Roche) and detected using the 
ultraView Universal DAB Detection kit (Ventana/Roche). For Ki-67 staining, sections were 
subjected to HIER in Tris-based buffer (CC1, Ventana/Roche), incubated with a mouse 
monoclonal Ki-67 antibody (MIB-1, Dako/Agilent Technologies) and Amplification kit reagents 
(Ventana/Roche), and detected with the ultraView Univerasl DAB Detection kit. Ki-67/MIB-1 
labeling index was assessed visually/microscopically by counting the percentage of positively 
stained nuclei in five randomly selected high-power magnification (400x) fields.
Frozen sections (5µm) for CTHRC1 detection were fixed with 4% paraformaldehyde for 25 
minutes, permeabilized in 0.1% Triton X-100 in PBS for 10 minutes and incubated in peroxidase-
blocking solution (Dako/Agilent Technologies) for 10 minutes. Sections were blocked in 5% BSA 
and 10% normal goat serum in PBS for 1 hour and incubated with the rabbit polyclonal antibody 
against CTHRC1 (11647-RP02, Sino Biological Inc., Beijing, China, 1:780) in PBS containing 
5% normal goat serum at 4°C overnight. In type I collagen (COL-I) staining, frozen sections were 
incubated in 0.3% H2O2 in methanol for 30 minutes and blocked in 5% normal goat serum. 
Sections were then incubated with the mouse monoclonal antibody to COL-I (ab6308, Abcam, 
1:2500) in PBS containing 5% normal goat serum at 4°C overnight. Immunodetection was 
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performed using the Vectastain ABC kit (Vector Laboratories) according to the manufacturer’s 
protocol using AEC as the chromogen. 
As negative controls, the primary antibodies were replaced by normal (isotype control) mouse or 
rabbit IgG in all stainings. All sections were counterstained with Mayer’s hematoxylin and 
mounted with Faramount (Dako/Agilent Technologies). Images were taken using a Nikon Eclipse 
80i microscope, a Digital Sight DS-5M camera, and the NIS-Elements F 2.20 software (Nikon, 
Tokyo, Japan). Tissue sections stained for cleaved caspase 3 were scanned using the 3DHISTECH 
Pannoramic 250 FLASH II digital slide scanner at the Genome Biology Unit (University of 
Helsinki and Biocenter Finland). Quantification of the cleaved caspase 3-positive cells in the 
whole tumor sections was performed using the HistoQuant module of the CaseViewer 
(3DHISTECH) and Fiji ImageJ 1.51.
2.6 TUNEL assay
Apoptotic and necrotic cells with DNA strand breaks were analyzed with TUNEL (Terminal 
deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling) staining using the In Situ Cell 
Death Detection Kit, TMR red (Roche) according to the manufacturer’s recommendations. 
Briefly, formalin-fixed paraffin-embedded sections were first deparaffinized and rehydrated in 
graded alcohol series. Sections were then treated with proteinase K (15 µg/ml in 10mM Tris-HCl, 
pH 7.5) at +37°C for 25 min and incubated with the TUNEL reaction mixture at +37°C for 1 hour. 
Finally, sections were stained with DAPI and mounted with Mowiol (Sigma-Aldrich). Images 
were generated using 3DHISTECH Pannoramic 250 FLASH II digital slide scanner at the 
Genome Biology Unit (University of Helsinki and Biocenter Finland). Quantification of the 
TUNEL- and DAPI-positive cells in the whole tumor sections was performed using Fiji ImageJ 
1.51. TUNEL-positive cells were quantified as the percentage of the total number of cells (nuclei 
stained by DAPI) per tumor sections in all xenograft tumors.
2.7 Western blotting
We performed the analysis of proteins from whole-cell extracts (Kielosto et al., 2004) and 
conditioned media (Ravanko et al., 2004, Nummela et al., 2012) as previously described. Briefly, 
proteins in 1x Laemmli sample buffer were resolved in 10% polyacrylamide gels and transferred 
on to nitrocellulose (Bio-Rad, Hercules, CA, USA) or PVDF membranes (Immobilon-FL, Merck, A
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Darmstadt, Germany). After blocking with 2% BSA, membranes were incubated with the primary 
antibodies overnight at +4°C. A panel of P4HA1 antibodies (NB100-57852 and NBP1-84398 from 
Novus Biologicals; 12658-1-AP and 66101-1-Ig from Proteintech Group) were tested for their 
performance in Western blotting, and the goat pAb NB100-57852 was selected for the study. The 
specificity of the antibodies was validated by analyzing the P4HA1 protein in control shRNA and 
P4HA1-knockdown (P4HA1-KD) cells. In addition, rabbit pAb ab85739 (Abcam, Cambridge, 
UK) was used to detect CTHRC1 protein. Mouse mAbs to alpha-tubulin (DM1A, Abcam) and 
alpha-actin (JLA20, Merck) were used as loading controls. Immunodetection was performed with 
chemiluminescence using horseradish peroxidase-conjugated secondary antibodies (Dako/Agilent 
Technologies) and the Clarity Western ECL Substrate (Bio-Rad) or with the Odyssey imaging 
system using IRDye secondary antibodies (LI-COR Biotechnology, Lincoln, NE, USA). The 
densities of the protein bands were quantified using ImageJ (1.47v; NIH, Bethesda, MD, USA) or 
Image Studio Lite (LI-COR Biotechnology, Lincoln, NE, USA).
2.8 Cell culture and reagents
We isolated and cultured primary human melanocytes as described elsewhere (Alanko et al., 
1999). Melanoma cell lines as well as the primary human embryonic fibroblasts and microvascular 
endothelial cells were obtained and cultured as previously described (Eriksson et al., 2016).
The prolyl 4-hydroxylase inhibitor 3,4-dihydroxybenzoic acid (DHB) was purchased from Abcam 
(ab142937).
2.9 Short hairpin RNA lentiviral particle transduction
WM239 and SKMEL-28 melanoma cells were transduced with Mission lentiviral transduction 
particles (SHCLNV) targeting P4HA1 (TRCN 0000303933) (P4HA1 shRNA cell pools 1 and 2) 
or with Mission TRC2 pLK0.5-puro non-target shRNA control particles (SHC216V) from Sigma-
Aldrich/Merck, or with shRNA lentiviral particles targeting P4HA1 (sc-90782-V) (P4HA1 shRNA 
cell pools 3 and 4) or with control shRNA particles (sc-108080) from Santa Cruz Biotechnology 
(Dallas, TX, USA) according to the manufacturer’s instructions. Pools of puromycin-resistant cells 
were used in the assays. 
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2.10 Transfection of CRISPR double nickase plasmids
WM239 and SKMEL-28 cells were transfected with P4HA1 double nickase plasmids (sc-407173-
NIC, Santa Cruz Biotechnology) or with control double nickase plasmids (sc-437281) using 
Lipofectamine 3000 (Thermo Fisher Scientific) according to manufacturer’s instructions. After 
puromycin selection, GFP-positive cell colonies were cylinder-cloned and assayed for P4HA1 
downregulation by Western blot.
2.11 RNA sequencing and data analysis
RNA sequencing library preparation, sequencing, and data analysis was performed at the 
Biomedicum Functional Genomics Unit (FuGU, University of Helsinki, Finland). Shortly, RNA 
sequencing libraries were prepared from two WM239 parental cell pools, control shRNA pools 2 
and 3, and P4HA1 shRNA pools 1-4 using the NEBNext Ultra II Directional RNA Library Prep-
kit (New England Biolabs, Ipswich, MA) according to the manufacturer’s instructions after 
purification of mRNA with polyA-binding beads. Sequencing was performed with Illumina 
NextSeq sequencer (Illumina, San Diego, CA) using a 75 bp pair-end Mid Output sequencing kit. 
RNA sequencing data quality was assessed with FastQC, and the data was quality trimmed with 
Trimmomatic. Reads were aligned to the genome (hg38, GRCh38.p12) with STAR software and 
gene counts were quantified with featureCounts (using gencode release 28 annotations). 
Differentially expressed genes (Benjamini-Hochberg-adjusted p-value < 0.05) were identified 
using the DESeq2 software in R.
2.12 Immunofluorescence staining
Cells were grown on glass coverslips in normal growth medium for four days and incubated in 
serum-free medium for 24 hours, after which the cells were fixed with 4% paraformaldehyde for 
30 min. After permeabilization with 0.1% Triton X-100 in PBS for 10 min and blocking with 1% 
BSA (Invitrogen/Thermo Fisher Scientific) and 10% normal goat serum in PBS for 1 hour, the 
cells were incubated with 1.5 µg/ml of rabbit pAb to P4HA1 (12658-1-AP, Proteintech Group) 
diluted in PBS containing 5% normal goat serum for 2 hours. Then, cells were washed three times 
with PBS and incubated with Alexa Fluor 488-conjugated goat anti-rabbit secondary antibodies 
(Invitrogen/Thermo Fisher Scientific) in PBS containing 1% normal goat serum. F-actin was 
detected with the Alexa Fluor 594-conjugated phalloidin (Molecular Probes/Thermo Fisher 
Scientific). Finally, the cells were mounted with the Vectashield H-1200 mounting media A
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containing DAPI (Vector Laboratories), and images were obtained using a Zeiss Axiophot2 
epifluorescence microscope (Carl Zeiss, Oberkochen, Germany), QImaging Retiga 4000R digital 
camera, and QCapture Pro 6-software (QImaging, Surrey, Canada).
2.13 Cell adhesion assay
Flat-bottomed 96-well plates were coated with 100 μl of 10 μg/ml COL-I (BD Biosciences, 
Franklin Lakes, NJ, USA) or cellular fibronectin (USBiologicals, Salem, MA) for 2 hours at 37°C, 
and washed three times with PBS. Cells (2.5 x 104) were added to uncoated or COL-I- or 
fibronectin-coated wells in serum-free RPMI 1640 medium (Sigma-Aldrich/Merck). Cell 
attachment and spreading were recorded by photography and the cells with different morphologies 
were counted after 2 to 72 hours incubation at 37°C. Attached, spread cells were defined as cells 
with flattened or elongated morphology, and round cells were considered unattached.
2.14 Cell apoptosis and viability assay
Cells used in the cell adhesion assay were stained with the CellEvent Caspase-3/7 Green Ready 
Probes Reagent to visualize apoptotic cells and with the cell membrane-impermeable propidium 
iodide from the Ready Probes Cell Viability Imaging Kit, blue/red (both from Thermo Fisher 
Scientific) to visualize dead cells with porous membrane according to the manufacturer’s 
instructions. Images of the cells were obtained using a Olympus IX71 microscope and DP70 
camera (Olympus, Center Valley, Philadelphia).
2.15 Three-dimensional Matrigel invasion assays
Melanoma cell invasion was assayed in a 3D growth factor–reduced Matrigel (BD Biosciences) as 
previously described (Kääriäinen et al., 2006, Ravanko et al., 2004). Briefly, cells (3 x 104) were 
cast between two Matrigel (3.3 mg/ml) layers, and the serum-free melanocyte growth medium M2 
supplemented with the growth factor Supplement Mix (PromoCell, Heidelberg, Germany) was 
added on top of the gel (replenished every third day). The invasion patterns of the cells were 
analyzed daily using microscopy and photography.
2.16 Xenograft tumor models
Animal studies were carried out according to the Animal Experiment Board in Finland (ELLA) for 
the care and use of animals under the licenses ESAVI-6285-04.10.07-20151. WM239 cells [6 x A
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106 cells in 100 µl of Opti-MEM I (Gibco/Thermo Fisher Scientific)] expressing P4HA1 shRNA 
(pool 2; Sigma-Aldrich/Merck shRNA) or control shRNA (pool 1) were injected subcutaneously 
into the lower flank of 5-week-old female NMRI-Foxn1 nu/nu mice (n = 8-9/group, one 
inoculation per animal). Tumor growth was followed two to three times a week using a caliper 
(measurements in three dimensions), and the mice were euthanized at day 36 when the largest 
tumors reached the ethical limits. The tumors were removed, cut in half, and one half was fixed in 
formalin and embedded in paraffin and the other half was frozen in isopentane. For histological 
and immunohistochemical analyses, the tumors were cut into 5-µm sections and stained with H&E 
and Masson’s trichrome and antibodies against P4HA1, COL-IV, COL-I, CTHRC1, CD31, 
cleaved caspase 3, and Ki-67 as described in the Histology and immunohistochemistry section 2.5. 
In addition, the tumor sections were analyzed for apoptotic cell death and necrosis with the 
TUNEL assay (section 2.6).
2.17 Statistical analysis
Statistical analyses were performed using a two-tailed Welch’s t-test, where we considered p < 
0.05 significant. Survival curves were plotted according to the Kaplan-Meier method and 
compared using the log-rank test in the SPSS 25.0.0.1 software program (SPSS, Chicago, USA). 
Median mRNA expression value of each gene was used as a cut-off value to classify samples into 
groups with low and high gene expression. Univariable and bivariable Cox regression analyses 
were performed using the SPSS program.
3 Results
3.1 Microarray analysis of primary melanomas
We have previously performed a preliminary search for potential markers of poor prognosis in 
primary melanomas (Eriksson et al., 2016). Here, we wanted to determine the gene expression 
profiles of aggressive primary melanomas and melanomas that showed a better outcome in a 
longer follow-up study. The samples were obtained from patients who had died of melanoma in 
less than two years after diagnosis (n = 7; median survival time 15 months, range 2-19 months; 
Breslow's thickness: average = 8.3 mm, median = 7.0 mm) or were alive with at least two years of 
follow-up (n = 12; median follow-up time = 90 months, range = 28-145 months; Breslow's 
thickness: average = 4.7 mm, median = 1.4 mm). We performed Significance Analysis of A
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Microarrays (SAM) to find genes correlating with patient disease-specific survival. SAM survival 
analysis identified 563 genes whose expression correlated with short patient survival time (Table 
S2) and 974 genes whose expression correlated with long survival time (Table S3). To determine 
whether these genes are specifically associated with certain processes and pathways, we 
performed a Gene Set Enrichment Analysis (GSEA) using the Hallmark gene set collection and 
found that the genes associated with short survival were especially over-represented in the 
epithelial-mesenchymal transition (EMT)-gene set (Table S4). In other gene set collections, our 
short survival genes were enriched among others in focal adhesion and extracellular matrix 
(ECM)-receptor-interaction (KEGG pathways), ECM organization and collagen formation 
(Reactome pathways), as well as angiogenesis (Gene Ontology Biological process) (Table S4).
To further clarify if the above potential prognostic marker genes might be upregulated specifically 
in the malignant melanoma cells, we compared the expression levels of the marker genes in 
primary melanomas and normal nevi as well as in melanoma cell lines (WM793 and WM239) and 
normal 42V melanocytes (Tables S2 and S3). The most interesting, potentially malignancy-
associated genes associated with short survival were prolyl 4-hydroxylase subunit alpha 1 
(P4HA1), Ras homolog gene family, member C (RHOC), serpin peptidase inhibitor, clade A, 
member 3 (SERPINA3), and fibronectin (FN1). We then also analyzed the potential of our top 
survival marker genes as predictors of melanoma patients’ overall survival in an independent, 
publicly available RNA sequencing dataset of primary melanomas (GEO accession: GSE98394: n 
= 44). In this dataset, the median follow-up time of the patients was 93 months, and the follow-up 
time for long-term survivors was at least 6 years. Median Breslow’s thickness of the primary 
melanomas was 2.6 (range 0.24-34) mm. We classified the patients into two groups according to 
the mRNA expression levels of each of the potential marker genes (the median expression values 
of all primary melanoma samples were used as cut-off values), and found that the Kaplan-Meier 
10-year overall survival curves differed highly significantly (Log-rank test, p < 0.001) between the 
groups when the expression levels of our short survival markers P4HA1, RHOC, SORT1, CD63, 
or CDK2AP1 (Fig. S2; Table S5, showing genes with p < 0.05) or long survival markers FOXN3, 
EGFR, DSC3, CLDN1, PTBP3, or CXADR (Fig. S3; Table S6; showing genes with p < 0.05) 
were used as classifiers. Expression values for SERPINA3 and SNHG5 were not reported in this 
data set. In univariable Cox regression analyses, the expression of FOXN3, EGFR, DSC3, 
CLDN1, PTBP3, or CXADR was significantly associated with longer overall survival (p < 0.01), 
and the expression of P4HA1, RHOC, SORT1, CD63, or CDK2AP1 was significantly associated A
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with shorter overall survival (p < 0.01), as was Breslow’s thickness (p = 0.014), which was 
dichotomized using 2 mm as a cut-point value (≤ 2mm and > 2mm). The expression of P4HA1, 
RHOC, SORT1, CD63, and CDK2AP1 remained significantly associated (p < 0.05) with shorter 
survival and EGFR, PTBP3, and CXADR with longer survival after adjusting for Breslow’s 
thickness in bivariable Cox regression models, suggesting that these genes are independent 
candidate markers of melanoma patient survival. We chose to study further P4HA1 in melanoma 
progression to assess its potential as a prognostic marker and therapeutic target.
3.2 P4HA1 is highly expressed in melanoma cells and fibroblasts
P4HA1 encodes one of the alpha subunits of prolyl 4-hydroxylase, a key enzyme in the synthesis 
of collagens, composed of two identical alpha subunits and two beta subunits. A dimer of P4HA1 
forms the catalytically active site of prolyl 4-hydroxylase I enzyme, which is the most common 
form in many cell types and tissues [reviewed in (Myllyharju, 2003)]. As fibroblasts have been 
reported to be important producers of P4HA1, we wanted to confirm that P4HA1 is also expressed 
by melanoma cells. There are four P4HA1 transcript variants encoding three different P4HA1 
protein isoforms, although it is not known if these isoforms have different functions. We first 
analyzed the mRNA expression levels of all P4HA1 transcript variants in melanoma cell lines and 
in primary cultures of human embryonic fibroblasts, microvascular endothelial cells, and normal 
melanocytes. P4HA1 variant 1 (encoding isoform 1) as well as variants 2 and 3 (encoding isoform 
2) were expressed at a similar or higher level in most melanoma cell lines compared to fibroblasts 
(Fig. 1A). Fibroblasts showed a little higher expression of the shorter transcript variant 4 
(encoding isoform 3) than most melanoma cell lines. Normal melanocytes and microvascular 
endothelial cells, in turn, showed lower expression of all the variants than most melanoma cell 
lines. We then analyzed the protein expression levels of human embryonic fibroblasts and two 
melanoma cell lines WM239 and SKMEL-28, which expressed P4HA1 mRNA at high level. The 
antibody we used in Western blot analyses recognizes the P4HA1 protein isoforms 1 and 2. At the 
protein level, embryonic fibroblasts showed higher expression of P4HA1 compared to the 
melanoma cell lines (Fig. 1B).
We also analyzed the expression and localization of P4HA1 in primary melanoma tissues (n = 27) 
by immunohistochemical staining. P4HA1 was mainly expressed by melanoma cells (Fig. 2A-O) 
but fairly often also by fibroblasts surrounding the melanoma cell nests (Fig. 2G-O), and by 
fibroblasts in the upper dermis (Fig. S1J,K). The intensity of the staining varied from negative to A
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strong positive even in individual melanoma samples. Staining in normal nevi (n = 8) varied from 
negative to moderate (Fig. 2P-R).
3.3 Knockdown of P4HA1 reduces cell adhesion, invasion, and survival of melanoma cells
To explore the function of P4HA1 in melanoma, we silenced the expression of P4HA1 in WM239 
melanoma cells. In the P4HA1 shRNA cell pools, the P4HA1 protein downregulation varied from 
52% to 93% compared to the parental and control shRNA cells as measured by Western blot 
analyses (Fig. 3A,B). P4HA1 protein downregulation was also confirmed by immunofluorescence 
staining (Fig. S4).
As P4HA1 is needed for collagen secretion and deposition in the ECM, we first studied the effect 
of P4HA1 downregulation on melanoma cell adhesion in uncoated wells in serum-free medium. 
We found that cell adhesion and spreading were significantly reduced in the P4HA1-knockdown 
(P4HA1-KD) cells compared to the parental and control shRNA cells after 2, 24, and 48 hours 
(Fig. 3C,D). Notably, when plated on type I collagen (COL-I)-coated wells, both the control and 
P4HA1-KD cells initially attached and spread well, but the attachment and spreading were 
reduced at the later 24 and 48 hour time points (Fig. 3E). This suggested that P4HA1 may also be 
needed for cell survival. Indeed, apoptosis and cell death by undefined mechanisms were found to 
be significantly increased in the P4HA1-KD cells compared to the control shRNA cells at the later 
time points (Fig. 3F,G). We then studied the effect of P4HA1 on melanoma cell invasion in 3D 
Matrigel and found that the knockdown of P4HA1 markedly reduced the invasive growth of 
WM239 cells (Fig. 3H).
We have also tried to knock out P4HA1 in WM239 cells using a CRISPR-Cas9 (D10A mutated 
double-nickase)-mediated system but have not yet obtained complete P4HA1 knockouts. 
However, we have obtained clones (by cylinder cloning) with 84% to 90% reduction in P4HA1 
protein levels (Fig. S5A). It remains to be seen by single cell cloning analyses whether it is a 
question of heterozygous or mixture of clones, and if it will even be possible to get a complete 
knockout. Nevertheless, already the partial knockout clones showed reduced cell adhesion ability 
compared to the control cells (Fig. S5B-E).
Prolyl 4-hydroxylases catalyze the hydroxylation of proline into 4-hydroxyproline in the Y 
position of the GXY triplets (where G is glycine and X is often proline or lysine) within the triple-
helical domains of collagens and other proteins [reviewed in (Gorres and Raines, 2010)]. To find A
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possible targets of P4HA1 in melanoma cell lines, we checked the expression levels of genes 
encoding collagen domain-containing proteins in a publicly available microarray data of 62 
melanoma cell lines (E-GEOD-7127). CTHRC1 showed the highest average expression (30 genes 
with highest expression are shown in Table S7). CTHRC1 was also highly upregulated in WM239 
and WM793 melanoma cell lines compared to normal melanocytes (Table S7). We have 
previously reported that CTHRC1 is overexpressed in metastatic primary melanomas and plays an 
important role in melanoma cell migration and invasion (Eriksson et al., 2016). As prolyl 4-
hydroxylation of the collagen triple helical domain has been shown to affect the secretion of 
collagens and complement C1q protein (Muller et al., 1978), we wanted to study if P4HA1 has an 
effect on CTHRC1 secretion. Indeed, we found that the knockdown and knockout of P4HA1 in 
WM239 cells increased (up to 300%) the amount of intracellular CTHRC1 (Figs 4A and S6A,C,E) 
and reduced (up to 85%) the amount of secreted CTHRC1 (Figs 4B and S6B,D,F) compared to 
those of parental and control cells. P4HA1 depletion had no effect on CTHRC1 mRNA levels as 
quantified by semiquantitative RT-PCR (Fig. S6G) or RNA sequencing. CTHRC1 mRNA 
expression levels were 4049 ± 1019 in parental and control shRNA WM239 cells (n = 4) and  
4170 ± 1210 in the P4HA1-KD cells (n = 4).
Next, we inhibited the activity of prolyl 4-hydroxylases using a competitive inhibitor 3,4-
dihydroxybenzoic acid (DHB). Treatment with DHB increased the amount of intracellular 
CTHRC1 and reduced CTHRC1 secretion in WM239 (Fig. 4C,D) as well as in SKMEL-28 
melanoma cells (Fig. 4E,F). When analyzed using non-reducing Western blotting, it appeared that 
especially the 25-kDa monomeric form of CTHRC1 increased in the cell extracts and the high-
molecular-weight multimers (>100 kDa) decreased in the secreted proteins of P4HA1-KD cells 
and after DHB treatment (Fig. S7).
We further studied the effect of inhibition of prolyl 4-hydroxylases on SKMEL-28 cell adhesion 
and survival in serum-free medium. DHB significantly reduced cell adhesion (Fig. 5A,B) and 
increased apoptosis and cell death  (by undefined mechanism) on uncoated surfaces (Fig. 5A,C). 
When plated on COL-I-coated wells, no difference in the adhesion between the untreated and 
DHB-treated cells could be detected two hours after plating, and both cells showed increased 
adhesion compared to the uncoated surfaces (Fig. 5D). However, adhesion of DHB-treated cells 
was again reduced after 48 and 72 hours compared to the untreated cells, although less markedly 
than on the uncoated surfaces (Fig. 5B,D). In addition, apoptosis and cell death by undefined A
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mechanism were also significantly increased in the DHB-treated compared to the untreated cells 
(Fig. 5E). Similar results were obtained on fibronectin-coated surfaces (Fig. S8).
When we silenced or knocked out P4HA1 in SKMEL-28 cells, a 56% to 84% reduction in the 
P4HA1 protein levels was detected (Fig. S9A,C), but the effect on cell adhesion was only minor. 
Downregulation of P4HA1 increased the amount of intracellular CTHRC1 (Fig. S9A,C) but 
unexpectedly did not significantly reduce the amount of secreted CTHRC1 (Fig. S9B,D). As the 
prolyl 4-hydroxylase inhibitor, however, showed similar effects (an increase in the intracellular 
content of CTHRC1 and a clear decrease in secreted CTHRC1) in both SKMEL-28 and WM239 
cell lines (see Fig. 4C-F), we analyzed the expression level of the other common prolyl 4-
hydroxylase α subunit, P4HA2. SKMEL-28 cells showed markedly higher P4HA2 mRNA 
expression compared to WM239 cells (Fig. S9E), suggesting that P4HA2 may compensate for the 
depletion of P4HA1 in P4HA1-KD and -knockout SKMEL-28 cells.
3.4 P4HA1 expression is associated with hypoxia, glycolysis, and MTORC1 signaling
To reveal which processes P4HA1 may be associated with in melanoma, we studied which genes 
show correlated mRNA expression to that of P4HA1 in a panel of 62 melanoma cell lines (E-
GEOD-7127). Many hypoxia-regulated genes, including MIR210HG, P4HA2, BNIP3, 
ANGPTL4, VEGFA, PLOD1, and HIF1A showed positive correlation (genes with highest 
correlation are shown in Table S8). We subjected the gene list to GSEA to find if these genes may 
be associated with other pathways and found that in addition to hypoxia these genes were over-
represented in EMT, glycolysis, MTORC1 signaling, and inflammatory response of HALLMARK 
gene sets (Table S9). We also found that genes that correlated with P4HA1 mRNA expression in 
primary melanoma tissues (n = 103, the Cancer Genome Atlas, TCGA) were over-represented in 
hypoxia, glycolysis, and MTORC1 signaling (Table S9).
3.5 P4HA1 knockdown affects a small set of invasion-associated genes
To further elucidate the function of P4HA1 in melanoma, we performed genome-wide gene 
expression analysis of the WM239 P4HA1-KD cells. RNA sequencing revealed that the 
knockdown of P4HA1 (downregulated over 5-fold compared to the parental and control shRNA 
cells) resulted in only moderate changes in expression levels of few genes (Table S10). The genes 
downregulated in P4HA1-KD cells included, among others, an ECM and basement membrane 
constituent, laminin α5 (LAMA5), and spire type actin nucleation factor 1 (SPIRE1). The most A
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significantly upregulated genes in P4HA1-KD cells were, in turn, potassium voltage-gated channel 
subfamily E regulatory subunit 4 (KCNE4) and Dickkopf WNT signaling pathway inhibitor 1 
(DKK1) (Table S10).
3.6 P4HA1 knockdown affects the architecture of WM239 melanoma tumors
To study the effect of P4HA1 on in vivo tumorigenesis, we injected the WM239 P4HA1-KD and 
control shRNA cells (6x106) subcutaneously into the lower flanks of nude mice. As P4HA1 
expression correlated with poor patient survival in human primary melanoma samples, we 
unexpectedly observed that P4HA1 knockdown increased tumor size in nude mice (Fig. 6). When 
the tumors were excised at day 36, the P4HA1-KD tumors were, however, found to be markedly 
less compact than the control tumors. We first confirmed the downregulation of P4HA1 in the 
knockdown tumors by immunohistochemical staining (Fig. 7A,B). In the H&E staining the 
P4HA1-KD tumors showed increased hemorrhage, large necrotic areas, and altogether a more 
loosened tissue architecture than the control tumors (Figs. 7C-F and S10A-D). In addition, 
although the control tumors were smaller, we found extensive invasion through the cutaneous 
striated muscle layer, panniculus carnosus (see also Nummela et al., 2012), towards the epidermis 
and/or fat tissue invasion (Figs. 7C,E and S10E-I) in six of the nine control tumors and only in two 
of the eight P4HA1-KD tumors. As the prolyl 4-hydroxylase is a key enzyme in collagen synthesis 
and deposition, we stained the tumors with Masson’s trichrome to see if P4HA1 knockdown 
affects the fibrillar collagen content of the tumors. In the control tumors, we found abundant 
collagen fibers surrounding tumor cells/cell nests and intratumoral blood vessels (Fig. 7G,I). The 
P4HA1-KD tumors showed markedly weaker collagen staining, indicating reduced collagen 
deposition, especially around blood vessels (Figs. 7H,J and S10J,K). The vessels walls were also 
frequently ruptured in the P4HA1-KD tumors, showing leakage of red blood cells (Figs. 7J and 
S10J,K). As the P4HA1-KD tumors appeared to be highly hemorrhagic, we further studied if there 
are changes in the amount of type IV collagen (COL-IV) in the basal lamina of the tumor blood 
vessels. Many blood vessels in the P4HA1-KD tumors showed reduced and fragmentary COL-IV 
deposition compared to the control tumors (Fig. 7K-N). The overall assembly of COL-IV 
networks around the tumor cells was also severely reduced in P4HA1-KD tumors, as compared to 
the control tumors  showing strong COL-IV staining around tumor cells and cell nests (Fig. 7K-
N). No difference in the mRNA levels of the major COL-IV chains was detected between the 
control and P4HA1-KD cells (COL4A1 and COL4A2 mRNA expression levels were 11688 ± 571 A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd.
and 18409 ± 942 in parental WM239 and control shRNA cells, respectively, and 10990 ± 423 and 
17465 ± 96 in P4HA1-KD cells, respectively). We further specifically studied the major fibrillar 
collagen COL-I, and found that its deposition was also reduced in the P4HA1-KD tumors 
compared to the controls (Fig. S11A-E). The control tumors showed more abundant, although 
heterogeneous staining of COL-I around tumor cells (Fig. S11A) and high COL-I expression 
around the tumor blood vessels (Fig. S11C). As we found P4HA1 knockdown to reduce the 
secretion of CTHRC1 in melanoma cells in vitro, and our previous results have shown that 
CTHRC1 is localized in the blood vessels in human melanomas (Eriksson et al., 2016), we further 
studied the expression of CTHRC1 in the xenograft tumors (Fig. S11F-J). The control tumors 
showed diffuse CTHRC1 staining in tumor cells and a more prominent staining around tumor 
blood vessels (Fig. S11F,H), while the P4HA1-KD tumors showed reduced CTHRC1 staining 
especially around tumor blood vessels (Fig. S11G,I). The blood vessel density (visualized by 
staining of the endothelial cell marker CD31) did not appear to markedly differ between the 
control and P4HA1-KD tumors (Fig. S12). However, the CD31 staining revealed frequent 
breakages of the endothelial cell layer in the blood vessels of the P4HA1-KD tumors (Fig. S12H).
To unravel the reasons for the larger tumor size in P4HA1-KD tumors, we also stained the tumors 
for the cell proliferation marker Ki-67. Both the control and P4HA1-KD tumors consisted of 
highly proliferative cells and showed no difference in their Ki-67 staining patterns (Fig. S13). 
Consistent with a recent publication (Miller et al., 2018), the Ki-67 staining of the nuclei was 
graded rather than binary (see Fig. S13, higher magnifications). The Ki-67 labeling indices varied 
from 70 to 90% in different regions of both the control and P4HA1-KD tumors, apparently 
depending on the growth rates and cell cycle phases of the heterogeneous tumor cells (Miller et 
al., 2018). The proliferation rates of the cells did not differ either in vitro. As the P4HA1-KD cells 
showed increased apoptosis under serum-free conditions in vitro, we further stained the tumors for 
cleaved caspase 3 (early apoptosis marker) to see if the silencing of P4HA1 also increases 
apoptosis in vivo. Seven of nine control and two of eight P4HA1-KD tumors contained only single 
isolated cells positive for the cleaved caspase 3 (Fig. S14A,B). The remaining two control tumors 
showed small clusters (Fig. S14C-D) and the six P4HA1-KD tumors larger clusters of apoptotic 
cells (Fig. S14E-J). The number of cleaved caspase 3-positive cells per tumor mm2 (calculated 
from the whole tumor sections) was significantly increased in the P4HA1-KD tumors (Fig. S14K, 
fold 2.2, p = 0.008). We further analyzed the tumors for late-stage apoptosis (and necrosis) by A
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TUNEL labeling. The P4HA1-KD xenografts showed significantly higher number of TUNEL-
positive cells compared to the control tumors (Fig. S15, fold 4.1, p = 0.019).         
4 Discussion
Melanoma, one of the most aggressive cancers, is a highly unpredictable disease and continues to 
be very difficult to cure. In this study, we aimed to find new prognostic markers and therapeutic 
targets based on the molecular pathways activated or deactivated in aggressive melanomas. The 
identified short survival genes were enriched especially in the EMT, ECM organization, collagen 
formation, and angiogenesis, all linked to the metastatic progression of tumors (Erler and Weaver, 
2009). RHOC, one of the potential short survival marker genes, encodes a small GTPase, which 
regulates the reorganization of the actin cytoskeleton and promotes EMT. RHOC expression has 
been found to associate with shorter disease-free and overall survival in melanoma patients, but 
not as an independent predictor (Boone et al., 2009). RHOC may also serve as a target for the 
cytotoxic T cells in patients with metastatic cancer (Wenandy et al., 2008), making it an 
interesting possible target for immunotherapy in melanoma. Also, the downregulation of one of 
our long survival marker genes, CXADR, encoding a tight junction protein, may enhance tumor 
progression by promoting EMT. Downregulation of CXADR appears to sensitize breast cancer 
cells to TGFβ-induced EMT, and its low expression correlates with poor prognosis in luminal A 
breast cancers (Nilchian et al., 2019).
Of our topmost novel prognostic marker genes for primary melanomas, P4HA1 seemed the most 
interesting as its expression was largely tumor cell-specific and upregulated in melanoma cell lines 
compared to normal melanocytes. Its mRNA expression is also reported to associate with poor 
survival in breast cancer (Gilkes et al., 2013b) and squamous cell carcinoma (Tawk et al., 2016, 
Kappler et al., 2017), and the P4HA1 protein expression correlates with poor prognosis in high-
grade gliomas (Hu et al., 2017). Our preliminary results from immunohistochemical staining of 
primary melanomas suggest that, in addition to P4HA1 mRNA levels, also high P4HA1 protein 
expression may be associated with increased metastasis and mortality and may serve as a 
prognostic factor (data not shown). In our gene set enrichment analysis, we found that P4HA1 is a 
part of a gene expression signature associated with hypoxia and glycolysis both in melanoma cell 
lines and in clinical melanoma primary tumors. Hypoxia is observed in most solid tumors and has 
been associated with poor patient outcome [reviewed in (Vaupel and Mayer, 2007)]. The A
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expression of hypoxia-induced genes or gene expression signatures [reviewed in (Harris et al., 
2015)] have been studied as surrogate markers for tumor hypoxia. Interestingly, Tawk et al. 
(2016) have tested three previously developed hypoxia gene signatures as prognostic factors in 
head and neck squamous cell carcinoma and found that the signature genes could be reduced to 
P4HA1, the only gene common in all signatures. P4HA1 expression is induced in hypoxia by the 
hypoxia inducible factor 1 (HIF-1) (Gilkes et al., 2013a), which regulates several pathways 
involved in tumor progression [reviewed in (Balamurugan, 2016)], such as EMT, angiogenesis, 
invasion, inflammation, and tumor metabolism, including the glycolytic pathway. P4HA1 
expression may also be regulated by hypoxia-independent factors, including TGFβ and 
USF1/USF2 transcription factors (Chen, L. et al., 2006). Further, other hypoxia-independent 
drivers, such as the oncogenic BRAFV600E mutation, have been found to increase HIF-1α protein 
(the oxygen-regulated subunit of HIF-1) and the expression of HIF-1-regulated genes in melanoma 
[reviewed in (Meierjohann, 2015)]. Recently, P4HA1 has also been found to stabilize HIF-1α 
independently of oxygen levels (Xiong et al., 2018), leading to a positive feedback loop and 
increased expression of HIF-1-induced genes. These results suggest an important role for P4HA1 
in HIF-1 signaling pathway and the potential of P4HA1 as a prognostic marker.
In our analyses of primary melanoma tumors, both the tumor cells and the stromal fibroblasts 
produced P4HA1, although the tumor cells appeared to be the main producers. Also in other 
cancers, such as gliomas and prostate cancer, P4HA1 staining has mostly been reported in the 
tumor cells (Zhou et al., 2017, Chakravarthi et al., 2014). This is interesting, as fibroblast are 
considered the main producers of collagens, which are the most important substrates for P4HA1. It 
seems, that at least in melanoma, the tumor cells may be responsible for the secretion of many 
collagens into their microenvironment. This was also evident in our xenograft model, where 
knockdown of P4HA1 in the melanoma cells led to reduced collagen deposition in the tumor 
tissues. As prolyl 4-hydroxylase is an intracellular enzyme and it affects the hydroxylation of 
newly synthesized procollagen chains, the majority of secreted collagen in the xenograft tumors 
seems to be produced by the melanoma cells and not the host stromal cells. As COL-IV staining 
was also reduced in the tumor blood vessels, it appears that melanoma cell-secreted COL-IV also 
contributes to the formation of basal lamina of the tumor blood vessels and thereby to the integrity 
of the vessels.
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Knockdown of P4HA1 has been reported to inhibit cancer cell proliferation in vitro and reduce 
tumor growth in xenograft models of breast and prostate cancer and gliomas (Gilkes et al., 2013b, 
Chakravarthi et al., 2014, Zhou et al., 2017). In our melanoma model, the silencing of P4HA1 did 
not appear to interfere with tumor cell proliferation in vitro or in vivo, as assessed by staining with 
the cell proliferation marker Ki-67. The P4HA1-KD tumors were, however, larger than the control 
tumors, but their tissue structure was very loose, likely due to the markedly reduced COL-IV 
network assembly and COL-I deposition in the ECM. P4HA1 knockdown has been shown to 
reduce tumor density and stiffness also in breast cancer xenografts (Gilkes et al., 2013b). 
Furthermore, our P4HA1-knockdown tumors were highly hemorrhagic, which could lead to the 
accumulation of fluid, partly explaining the larger volume of the tumors. Hemorrhages appeared to 
be caused by rupture of tumor blood vessels, weakened by the lack of COL-IV (normally 
providing structural support) in the basement membranes and in the surrounding tumor tissue. The 
knockdown of P4HA1 has also been found to inhibit the synthesis of COL-IV and disrupt the 
structures of vascular basement membranes in glioma xenografts (Zhou et al., 2017). Further, 
knockout of P4ha1 in mice is embryonic lethal, most likely due to deficient assembly of COL-IV 
(Holster et al., 2007). Our results also show that the expression of laminin α5 was downregulated 
in P4HA1-knockdown cells, which may further weaken the vascular basement membranes.
We have previously found that CTHRC1 is an important mediator of melanoma cell migration and 
invasion in vitro, and that in clinical melanoma tumor samples, CTHRC1 is expressed in 
melanoma cells, tumor-associated fibroblasts, and tumor blood vessels (Eriksson et al., 2016). 
Here, we show that P4HA1 knockdown reduced CTHRC1 secretion in melanoma cells in vitro 
and CTHRC1 protein deposition around tumor blood vessels in vivo. Interestingly, overexpression 
of CTHRC1 in endothelial cells and addition of the recombinant CTHRC1 have been found to 
promote endothelial cell migration and tubulogenesis in vitro (Lee et al., 2016, Fu et al., 2017). 
Further, CTHRC1 expression has been reported to correlate with increased blood vessel density in 
mouse pancreatic tumor xenografts (Lee et al., 2016) and in human gastrointestinal stromal tumors 
(Fu et al., 2017). Altogether, these data suggest an important role for CTHRC1 in P4HA1-
regulated neovascularization.
We further found that P4HA1 depletion inhibited the invasion of melanoma cells in vitro and in 
vivo. This has also been described for breast cancer xenograft tumors, where P4HA1 silencing 
inhibits tumor invasion and formation of lung and lymph node metastases (Gilkes et al., 2013b). A
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P4HA1 may promote tumor metastasis by enhancing the secretion of collagens, which form 
together with other extracellular molecules, such as fibronectin and periostin, fibrillar networks 
that regulate cell motility and invasion (Soikkeli et al., 2010). Also, laminin α5, which was 
downregulated in the P4HA1-knockdown cells, strongly promotes melanoma cell migration 
(Oikawa et al., 2011). P4HA1 may also enhance invasion by regulating the expression of 
invasion-associated genes, such as SPIRE1, which was downregulated, and DKK1, which was 
upregulated in the P4HA1-knockdown cells. SPIRE1 is an actin nucleator, which is a part of the 
invadosome and promotes matrix degradation (Lagal et al., 2014). DKK1, in turn, is a secreted 
inhibitor of Wnt signaling (Fedi et al., 1999), and its overexpression decreases the invasive 
capability of melanoma cells in vitro (Chen, J. et al., 2012) and increases apoptosis in melanoma 
cells in vitro and in vivo (Mikheev et al., 2007). How P4HA1 may regulate the expression of these 
genes, remains to be clarified, but one mechanism by which P4HA1 may affect gene expression is 
through stabilization of HIF-1α (Xiong et al., 2018).
We showed that both knockdown of P4HA1 expression and inhibition of the prolyl 4-hydroxylase 
activity reduced melanoma cell adhesion on uncoated surfaces in serum-free medium, suggesting 
that one function of P4HA1 in melanoma cells is to promote collagen production for their own 
adhesion and spreading. In accordance with this, the cells were able to adhere well to exogenous 
COL-I and fibronectin early after seeding. Cell adhesion and viability were, however, reduced 
after longer periods of incubation, suggesting that inhibition of prolyl 4-hydroxylase reduces some 
additional attachment or survival factors, resulting in apoptosis/anoikis. The silencing of P4HA1 
also increased apoptosis and cell death in vivo, but only in regions where the microenvironmental 
changes may have caused cellular stress, e.g. as a result of hemorrhages and hypoxia/anoxia.
Although the prolyl 4-hydroxylase inhibitor DHB showed a similar effect in both WM239 and 
SKMEL-28 cell lines, P4HA1 silencing only resulted in minor changes in the cellular behavior of 
the SKMEL-28 cells. This may be due to a compensatory effect of the other common prolyl 4-
hydroxylase alpha subunit, P4HA2, which was expressed at a higher level in SKMEL-28 cells 
than in WM239 cells, although previous studies have suggested that P4HA1 may largely 
compensate for the lack of P4HA2 but not vice versa (Holster et al., 2007, Aro et al., 2015). 
Further, in primary melanoma tumor samples (from GSE98349 dataset), P4HA2 was expressed at 
a lower level than P4HA1, and its mRNA expression was not significantly associated with 
survival (as analyzed by us), in concert with our data. In another study, high P4HA2 mRNA levels A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & 
Sons Ltd.
were reported to correlate with poor prognosis in a dataset comprised mostly of melanoma 
metastases (Atkinson et al., 2019). Of note, also high P4HA1 mRNA levels were significantly 
associated with shorter disease-specific survival in that dataset using the same cutoff parameters, 
although that was not reported in the study. In breast cancer, high P4HA1 and P4HA2 mRNA 
levels in primary tumors associate with poorer overall survival, and knockdown of either P4HA1 
or P4HA2 may reduce collagen deposition and inhibit tumor invasion and metastasis in vivo 
(Gilkes et al., 2013b). These data suggest that depending on the cell type and the relative 
expression levels of P4HA1 and P4HA2, inhibition of both prolyl 4-hydroxylase alpha subunits 
may be needed to effectively block the prolyl 4-hydroxylase function. Systemic treatment with a 
prolyl 4-hydroxylase inhibitor, ethyl 3,4-dihydroxybenzoate (EDHB), has been reported to 
decrease tumor fibrosis and metastasis in a breast tumor xenograft model (Gilkes et al., 2013b). 
However, the tumors were derived from P4HA1-overexpressing and HIF-1α- and HIF-2α-silenced 
MDA-MB-231 cells (as EDHB may stabilize HIF-1 and HIF-2 levels through inhibition of HIF 
prolyl 4-hydroxylases), complicating the interpretations. Many compounds that inhibit collagen 
prolyl 4-hydroxylases have been developed but suffer from poor selectivity (they also inhibit HIF 
prolyl 4-hydroxylases) or toxic off-target effects [reviewed in (Vasta and Raines, 2018)]. 
Altogether, therapeutic targeting of P4HA1 (and P4HA2) is an interesting possibility for the 
treatment of aggressive melanomas, and other cancers, but more specific inhibitors are still 
needed.
5 Conclusions
In summary, we identified several novel molecules associated with melanoma progression that 
could predict patient survival in primary melanomas, independent of the Breslow’s tumor 
thickness. Many of the identified potential prognostic marker genes were associated with 
processes linked to the metastatic progression of tumors, including EMT, ECM organization, 
collagen formation, and angiogenesis. We studied further the significance of one of these genes, 
P4HA1, in melanoma progression and show that P4HA1 depletion in melanoma cells reduced cell 
adhesion, invasion, and viability in vitro. Our melanoma xenograft model suggested that P4HA1 
knockdown also reduces melanoma invasion in vivo as well as the deposition of collagens, 
particularly COL-IV, in the interstitial ECM and in the basement membranes of tumor blood 
vessels. This compromises the overall tissue integrity and leads to rupture of blood vessel walls A
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and hemorrhages. Besides providing structural support, collagens also give signaling cues to cells 
and may regulate cell proliferation, apoptosis, angiogenesis, invasion, and metastasis (Fidler et al., 
2018, Wu and Ge, 2019, Nissen et al., 2019). Further, our results show that P4HA1 knockdown 
reduced the secretion of CTHRC1, an important mediator of melanoma cell migration and 
invasion, in vitro and its deposition around tumor blood vessels in vivo, suggesting that this 
angiogenesis-promoting molecule may also play an important role in P4HA1-regulated 
neovascularization. Taken together, P4HA1 is a highly interesting potential prognostic marker and 
therapeutic target, influencing many aspects of melanoma tumor progression.
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Figure Legends
Fig. 1. Expression of P4HA1 in melanoma cell lines and various primary cells. (A) Expression of 
different P4HA1 transcript variants in a panel of melanoma cell lines and different human primary 
cells analyzed by semiquantitative PCR. Beta-actin (ACTB) was used as a reference. Relative 
expression levels of each gene or variant compared to normal melanocytes are shown below. (B) 
Western blot analysis of P4HA1 protein expression in cell extracts of human embryonic 
fibroblasts and WM239 and SKMEL-28 melanoma cell lines. Alpha-actin was used as a loading 
control.   
Fig. 2. Expression of P4HA1 protein in primary melanomas and nevi. (A-O) Examples of primary 
melanomas that show different levels of P4HA1 expression in melanoma cells. Staining was also 
detected in the fibroblasts surrounding the melanoma cells in some samples (I, L, and O, marked 
with arrows). (P-R) P4HA1 expression in a benign nevus. Positive immunostaining is shown in 
red. (B, E, H, K, N, and Q) show a higher magnification of the boxed area in (A, D, G, J, M, and 
P, respectively) and (C, F, I, L, O, and R) in (B, E, H, K, N, and Q, respectively). Scale bars = 200 
µm (A, D, G, J, M, P), 100 µm (B, E, H, K, N, Q), 50 µm (C, F, I, L, O, R).
Fig. 3. Effect of P4HA1 silencing on cell adhesion, invasion, and apoptosis/viability of WM239 
cells in serum-free media. (A and B) Western blot analysis of P4HA1 protein expression in cell 
extracts of parental WM239, control (ctrl shRNA), and P4HA1-KD (P4HA1 shRNA) cells 
transduced with lentiviral shRNAs from Sigma-Aldrich/Merck (A) and from Santa Cruz 
Biotechnology (B). (C) Adhesion of parental WM239, control, and P4HA1-KD cells plated on 
uncoated wells in serum-free media and photographed after 2h, 24h, and 48h incubation. (D and 
E) The percentage of attached and spread cells plated on uncoated (D) and collagen-I-coated (E) 
surfaces. (F and G) Effect of P4HA1 silencing on apoptosis and cell death of WM239 cells in 
serum-free media. (F) WM239 control and P4HA1-KD cells were plated in serum-free media and 
photographed with phase-contrast and fluorescence microscopy after 48h incubation. Apoptotic 
cells (stained for activated caspase-3/7) are seen in green and dead cells (stained with propidium 
iodide) in red. Apoptotic, dead cells are seen in yellow. (G) The percentage of apoptotic cells 
(green and yellow) and cells died by undefined mechanism (red) incubated in serum-free medium 
for 48 hours. Data are expressed as means ± SD of three replicates. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p<0.0001. (H) Effect of P4HA1 silencing on the invasive growth of WM239 cells in A
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Matrigel. Parental WM239, control, and P4HA1-KD cells were embedded between two layers of 
Matrigel for 7 days prior the analysis. Scale bars = 100 µm.
Fig. 4. Effect of P4HA1 protein downregulation or treatment with a prolyl 4-hydroxylase inhibitor 
on CTHRC1 secretion in WM239 and SKMEL-28 cells. (A and B) Western blot analyses of 
CTHRC1 protein expression in cell extracts (A) and in the conditioned medium (B) of parental 
WM239, control (ctrl shRNA), and P4HA1-KD (P4HA1 shRNA) cells transduced with lentiviral 
shRNAs from Sigma-Aldrich/Merck. (C-F) Western blot analyses of CTHRC1 protein expression 
in cell extracts of WM239 (C) and SKMEL-28 (E) cells and in the conditioned medium of 
WM239 (D) and SKMEL-28 (F) cells incubated without or with a prolyl 4-hydroxylase inhibitor 
3,4-dihydroxybenzoic acid (DHB) for 18 hours. Alpha-tubulin was used as a loading control for 
cell extracts (A, C, and E) and silver staining to analyze the total secreted proteins in the 
conditioned medium (B, D, and F). The lower-molecular-weight bands of secreted CTHRC1 in the 
high-expressing control cells may represent some degradation products of CTHRC1.  
Fig. 5. Effect of prolyl 4-hydroxylase inhibition on cell adhesion and apoptosis/viability of 
SKMEL-28 cells plated on uncoated or collagen-I-coated surfaces. (A) SKMEL-28 cells were 
plated in serum-free media without or with a prolyl 4-hydroxylase inhibitor 3,4-dihydroxybenzoic 
acid (DHB) and photographed after 2h, 48h, and 72h incubation. Both phase-contrast and 
fluorescence images are shown after 72h incubation. Apoptotic cells (with activated caspase-3/7) 
are seen in green and dead cells (stained with propidium iodide) in red. Apoptotic, dead cells are 
seen in yellow. (B-E) The percentage of attached and spread cells (B and D), apoptotic cells (green 
and yellow) (C and E), and cells died by undefined mechanism (red) (C and E) when incubated in 
serum-free medium without or with DHB on uncoated (B and C) or collagen-I-coated (D and E) 
surfaces for 2, 24, and 72 hours (B and  D) or 72 hours (C and E). Data are expressed as means ± 
SD of three replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bars = 100 µm.
Fig. 6. Tumor growth of WM239 control and P4HA1-knockdown cells in nude mice. WM239 
control (ctrl shRNA) and P4HA1-KD (P4HA1 shRNA) cells (6 x 106) were injected 
subcutaneously into the lower flank of the mice (nine mice in the control group and eight mice in 
the P4HA1-KD group). Tumor volume was measured using a caliper two to three times a week. 
Bars represent standard deviations. * p < 0.05.
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Fig. 7. Histochemical analysis of xenograft tumors derived from WM239 control and P4HA1-
knockdown cells. (A-B) Representative images of P4HA1 immunostaining in WM239 control (ctrl 
shRNA) (A) and P4HA1-KD (P4HA1 shRNA) (B) tumors. Positive immunostaining is shown in 
red. (C-F) H&E staining in control (C and E) and P4HA1-KD (D and F) tumors. Muscle is stained 
light pink and red blood cells red. Invasion to muscle is marked with white arrows and to fat tissue 
with black arrows. (G-J) Masson’s trichrome staining in control (G and I) and P4HA1-KD (H and 
J) tumors. Collagen fibers are stained blue and red blood cells red. (K-N) Immunostaining of 
COL-IV in control (K and M) and P4HA1-KD (L and N) tumors. Positive immunostaining is 
shown in brown. (G-N) Examples of blood vessels are marked with asterisks. Scale bars = 100 µm 
(A,B,G-J, M,N), 200 µm (C-F,K,L). Note that the P4HA1-KD tumor sections are more prone to 
tearing due to the loosened tissue structure. 
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Supporting Information
Table S1. PCR variables.
Table S2. Significance Analysis of Microarrays (SAM) results of mRNA expression levels in 
primary melanomas associated most significantly with patient survival (higher expression in cases 
with short survival).
Table S3. Significance Analysis of Microarrays (SAM) results of mRNA expression levels in 
primary melanomas associated most significantly with patient survival (lower expression in cases 
with short survival).
Table S4. Gene Set Enrichment Analysis results for genes associated most significantly with 
patient survival.
Table S5. Kaplan-Meier survival analysis and mean survival times of patients with primary 
melanomas that show low and high mRNA expression of the top short survival marker genes in an 
independent RNA sequencing data set (GSE98394).
Table S6. Kaplan-Meier survival analysis and mean survival times of patients with primary 
melanomas that show low and high mRNA expression of the top long survival marker genes in an 
independent RNA sequencing data set (GSE98394).
Table S7. Expression levels of genes encoding collagen domain-containing proteins in 62 
melanoma cell lines (E-GEOD-7127).
Table S8. Genes correlating with P4HA1 expression in a panel of 62 melanoma cell lines (E-
GEOD-7127).
Table S9. Gene Set Enrichment Analysis results for genes that correlate with P4HA1 expression 
in melanoma cell lines and primary melanoma tissues.
Table S10. Gene expression changes in WM239 cells after knockdown of P4HA1 expression.
Fig. S1. Comparison of the staining patterns of P4HA1 antibodies in immunohistochemical 
analyses.
Fig. S2. Prognostic value of selected potential marker genes of short survival in primary 
melanomas.
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Fig. S3. Prognostic value of selected potential marker genes of long survival in primary 
melanomas.
Fig. S4. Knockdown of P4HA1 protein in WM239 cells.
Fig. S5. Effect of P4HA1 depletion on adhesion of WM239 cells in serum-free media.
Fig. S6. Effect of P4HA1 protein downregulation on CTHRC1 secretion in WM239 cells.
Fig. S7. Effect of P4HA1 protein downregulation or prolyl 4-hydroxylase inhibition on CTHRC1 
secretion.
Fig. S8. Effect of prolyl 4-hydroxylase inhibition on cell adhesion and apoptosis/viability of 
SKMEL-28 cells plated on fibronectin-coated surfaces.
Fig. S9. Effect of P4HA1 protein downregulation on CTHRC1 secretion in SKMEL-28 cells.
Fig. S10. Histochemical analysis of xenograft tumors derived from WM239 control and P4HA1-
knockdown cells.
Fig. S11. Immunohistochemical staining of COL-I and CTHRC1 in frozen sections of xenograft 
tumors derived from WM239 control and P4HA1-knockdown cells.
Fig. S12. Immunohistochemical staining of the endothelial cell marker CD31 in xenograft tumors 
derived from WM239 control and P4HA1-knockdown cells.
Fig. S13. Immunohistochemical staining of the cell proliferation marker Ki-67 in xenograft tumors 
derived from WM239 control and P4HA1-knockdown cells.
Fig. S14.  Immunohistochemical staining of the apoptosis marker cleaved caspase 3 in xenograft 
tumors derived from WM239 control and P4HA1-knockdown cells.
Fig. S15. Analysis of apoptosis (and necrosis) by TUNEL staining in xenograft tumors derived 
from WM239 control and P4HA1-knockdown cells. 
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